CD40 ligand‐expressing recombinant vaccinia virus promotes the generation of CD8+ central memory T cells

Central memory CD8+ T cells (TCM) play key roles in the protective immunity against infectious agents, cancer immunotherapy, and adoptive treatments of malignant and viral diseases. CD8+ TCM cells are characterized by specific phenotypes, homing, and proliferative capacities. However, CD8+ TCM‐cell...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European journal of immunology 2016-02, Vol.46 (2), p.420-431
Hauptverfasser: Trella, Emanuele, Raafat, Nermin, Mengus, Chantal, Traunecker, Emmanuel, Governa, Valeria, Heidtmann, Swantje, Heberer, Michael, Oertli, Daniel, Spagnoli, Giulio C., Zajac, Paul
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Central memory CD8+ T cells (TCM) play key roles in the protective immunity against infectious agents, cancer immunotherapy, and adoptive treatments of malignant and viral diseases. CD8+ TCM cells are characterized by specific phenotypes, homing, and proliferative capacities. However, CD8+ TCM‐cell generation is challenging, and usually requires CD4+ CD40L+ T‐cell “help” during the priming of naïve CD8+ T cells. We have generated a replication incompetent CD40 ligand‐expressing recombinant vaccinia virus (rVV40L) to promote the differentiation of human naïve CD8+ T cells into TCM specific for viral and tumor‐associated antigens. Soluble CD40 ligand recombinant protein (sCD40L), and vaccinia virus wild‐type (VV WT), alone or in combination, were used as controls. Here, we show that, in the absence of CD4+ T cells, a single “in vitro” stimulation of naïve CD8+ T cells by rVV40L‐infected nonprofessional CD14+ antigen presenting cells promotes the rapid generation of viral or tumor associated antigen‐specific CD8+ T cells displaying TCM phenotypic and functional properties. These observations demonstrate the high ability of rVV40L to fine tune CD8+ mediated immune responses, and strongly support the use of similar reagents for clinical immunization and adoptive immunotherapy purposes.
ISSN:0014-2980
1521-4141
DOI:10.1002/eji.201545554